Shivaani Kummar
Medical Oncology · Portland, ORNPI 1053612341
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $60,569 of the $66,391 with a category attached, or 91.2%. Bayer accounts for 60.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $20,347 and has fallen 58.3% since, to $8,477 in 2025. Among medical oncology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 47 payments — averaging $1412.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$40K
- Boehringer Ingelheim International GmbH$9K
- Gilead$6K
- Seagen Inc.$3K
- Mirati Therapeutics, Inc.$2K
- Illumina, Inc.$2K
- plus $4K from 6 others
Across 1,092 payments — averaging $7067.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$976K
- Otsuka Pharmaceutical Co., Ltd.$813K
- E.r. Squibb & Sons, L.L.C.$804K
- Deciphera Pharmaceuticals Inc.$797K
- Seagen Inc.$645K
- Modernatx, Inc.$586K
- plus $3.1M from 19 others
What the payments were for
- Consulting fees$60,56991%
- Speaking & faculty fees$3,8896%
- Grants$3210%
- Travel & lodging$1,0542%
- Food & beverage$5581%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 21 | $39,950 |
| Boehringer Ingelheim International GmbH | 4 | $8,581 |
| Gilead | 2 | $6,417 |
| Seagen Inc. | 8 | $3,374 |
| Mirati Therapeutics, Inc. | 3 | $2,475 |
| Illumina, Inc. | 1 | $2,084 |
| Daiichi Sankyo Inc. | 2 | $1,290 |
| Boehringer Ingelheim | 1 | $1,140 |
| Aadi Bioscience, Inc. | 1 | $550 |
| Day One Biopharmaceuticals | 1 | $321 |
| AstraZeneca | 2 | $190 |
| Sandoz | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$66,391 in reported general payments places this provider in the 90th percentile of 92 medical oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Portland
- David PagePortland$238K
- Rachel SanbornPortland$233K
- Matthew TaylorPortland$231K
- Tomasz BeerPortland$102K
- Alison ConlinPortland$85K
- Stacy LewisPortland$57K
- Hagen KenneckePortland$53K
- Adel KardoshPortland$51K
- Brendan CurtiPortland$49K
- Rom LeidnerPortland$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.